Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 37 (3) , 195-211
- https://doi.org/10.2165/00003088-199937030-00002
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell linesInternational Journal of Cancer, 1999
- PaclitaxelDrugs & Aging, 1998
- The TaxoidsDrugs, 1998
- Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroidsEuropean Journal Of Cancer, 1997
- EpirubicinDrugs, 1997
- Extended multidrug resistance in haemopoietic cellsBritish Journal of Haematology, 1996
- Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitroEuropean Journal Of Cancer, 1995
- Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.Journal of Clinical Investigation, 1995
- Antiproliferative activity of taxol on human tumor and normal breast cells vs. effects on cardiac cellsInternational Journal of Cancer, 1995
- Taxol in combination with doxorubicin or etoposide possible antagonism in vitroCancer, 1993